Rokhsana Mortuza

Rokhsana Mortuza

Auto-generated profile, based on publicly available information

Rokhsana Mortuza

Division of Gastroenterology and Hepatology, Western University & London Health Sciences Centre, London, Canada

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2025 in Hepatology Communications
Verified
Journal Article
Open access
FIFrancisco Idalsoaga
Francisco Idalsoaga
LDLuis Antonio Díaz
Luis Antonio Díaz
WDWinston Dunn
Winston Dunn
HMHeer Mehta
Heer Mehta
KMKaren Muñoz
Karen Muñoz
JAJuan Pablo Arab
Juan Pablo Arab
Background: Severe alcohol-associated hepatitis (sAH) is a well-characterized disease with high short-term mortality. However, there is limited research on those with a “less severe condition” (moderate AH). This study aims to characterize in-depth patients with moderate AH (mAH), including the performance of mortality scoring systems, key prognostic factors, and survival over time. Methods: A multicenter retrospective cohort study (2009–2019) included patients with mAH (MELD score ≤20 at admission). Cox regression and receiver operating characteristic curves with AUC were used for analysis. Results: We included 1845 patients with AH (20 centers, 8 countries) between 2009 and 2019. mAH was defined as a MELD score ≤20 at admission. Twenty-four percent met the criteria for an mAH episode. Patients with mAH tend to be older and have a higher proportion of females, with a median MELD of 17 (15–19), Maddrey discriminant function (mDF) of 33 (22–40), the trajectory of serum bilirubin of 0.83 (0.60–1.21), and neutrophil-to-lymphocyte ratio (NLR) of 5 (2.96–8.60). The primary causes of death in mAH included multiple organ failure (34.1%) and infections (16.6%). The cumulative survival rates at 30, 90, and 180 days were 94.3%, 90.4%, and 88.2%, respectively. In multivariable analysis, age was the only significant predictor of 30-day mortality (HR 1.49, 95% CI: 1.27–1.76, p<0.001). Mortality prediction models showed poor performance, with AUC for MELD (0.671), mDF (0.726), trajectory of serum bilirubin (0.733), and NLR (0.697). Conclusions: Patients with moderate AH exhibited a mortality of 11.8% at 6 months, primarily driven by multiple organ failure and infections. These patients also exhibit a different clinical profile compared to those with sAH. Tailored models and therapeutic strategies are needed to improve long-term outcomes in mAH.

18 February 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
FIFrancisco Idalsoaga
Francisco Idalsoaga
LDLuis Antonio Díaz
Luis Antonio Díaz
LGLeonardo Guizzetti
Leonardo Guizzetti
WDWinston Dunn
Winston Dunn
HMHeer Mehta
Heer Mehta
JAJuan Pablo Arab
Juan Pablo Arab
Several dynamic models predict mortality and corticosteroid response in alcohol‐associated hepatitis (AH), yet no consensus exists on the most effective model. This study aimed to assess predictive models for corticosteroid response and short‐term mortality in severe AH within a global cohort. We conducted a multi‐national study of patients with severe AH treated with corticosteroids for at least 7 days, enrolled between 2009 and 2019. Dynamic models—Lille‐4, Lille‐7, trajectory of serum bilirubin (TSB), and neutrophil‐to‐lymphocyte ratio (NLR)—were used to estimate 30‐ and 90‐day mortality. Lille‐7 demonstrated the highest accuracy for both 30‐ and 90‐day mortality.

24 October 2024 in Hepatology Communications
Verified
Journal Article
Open access
AIAlvi Husni Islam
Alvi Husni Islam
LDLuis Antonio Díaz
Luis Antonio Díaz
FIFrancisco Idalsoaga
Francisco Idalsoaga
LGLeonardo Guizzetti
Leonardo Guizzetti
RMRokhsana Mortuza
Rokhsana Mortuza
JAJuan Pablo Arab
Juan Pablo Arab
Export

27 November 2025 in Annals of Hepatology
Verified
Journal Article
Open access
YAYousef Almahanna
Yousef Almahanna
FIFrancisco Idalsoaga
Francisco Idalsoaga
LDLuis Antonio Díaz
Luis Antonio Díaz
AAAhmed Almohsen
Ahmed Almohsen
YSYi Nong Song
Yi Nong Song
JAJuan Pablo Arab
Juan Pablo Arab
Steatotic liver disease (SLD) affects 40 % of North Americans, with some progressing to advanced fibrosis. A recent nomenclature update redefined subtypes, distinguishing Metabolic dysfunction-associated steatotic liver disease (MASLD), Metabolic and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD). This study aimed to assess the prevalence of MetALD and ALD in a previously Non-alcoholic fatty liver disease (NAFLD) -labeled cohort, evaluate cardiometabolic risk factors, and analyze short-term outcomes. This retrospective observational cohort study included patients referred to a specialized NAFLD clinic in Ontario, Canada (October 2021-September 2023). Adults (age ≥18 years) with radiographic hepatic steatosis were categorized into MASLD, MetALD, or ALD based on gender-specific alcohol consumption thresholds documented in electronic medical records. Baseline characteristics and short-term outcomes were compared across groups. Among 445 patients, MASLD was most prevalent (88.3 %), followed by MetALD (8.9 %) and ALD (2.7 %). Males predominated in MetALD (67.5 %) and ALD (83.4 %) (p = 0.002). Smoking was strongly linked to ALD (p = 0.001). Diabetes was more common in MASLD (32.5 %, p = 0.012), while hypertension and dyslipidemia showed no significant differences across SLD subtypes. Advanced fibrosis (F3-F4) was present in 16.1 %. In a two-year follow-up, higher mortality incidences were observed in ALD (16.6 %). Additionally, regression of fibrosis was observed across all groups. 11.7 % of patients historically labeled as NAFLD met criteria for MetALD or ALD, underscoring the importance of updated nomenclature. High fibrosis prevalence and ALD-related mortality highlight the need for early screening, precise alcohol assessment, and multidisciplinary care to improve outcomes.